Renal Denervation for Hypertension
On this page
Direct answer
A rise, a fall and a second rise: renal denervation was celebrated after unblinded early registries, written off when the sham-controlled SYMPLICITY HTN-3 trial missed its primary endpoint in 2014, and rehabilitated by a second generation of trials. SPYRAL HTN-OFF MED showed catheter-based radiofrequency ablation of renal artery sympathetic fibres lowers 24-hour ambulatory systolic pressure by roughly 4-5 mmHg beyond sham in patients off medication, with the benefit persisting on background therapy (SPYRAL HTN-ON MED), and the ultrasound-based RADIANCE-HTN SOLO trial found a similar fall of about 6 mmHg. The procedure is an adjunct for uncontrolled or resistant hypertension or drug intolerance — never a replacement for pharmacological therapy — and only after secondary hypertension and adherence have been excluded.
What you must remember
- Anatomy of the intervention: ablation of both efferent sympathetic fibres (driving renin release and sodium retention) and afferent fibres (feeding central sympathetic tone) in the renal artery adventitia, performed percutaneously, bilaterally, spiral fashion.
- SYMPLICITY HTN-3 (2014): first rigorous sham-controlled trial — no significant office systolic difference versus sham; regression to the mean, medication changes and incomplete ablation blunted it.
- The rehabilitation: SPYRAL HTN-OFF MED (about -4 to -5 mmHg ambulatory systolic versus sham), SPYRAL HTN-ON MED (benefit on drugs), RADIANCE-HTN SOLO (ultrasound, roughly -6 mmHg daytime ambulatory).
- Patient profile: true resistant hypertension on three drugs including a diuretic at optimal doses, confirmed by ambulatory monitoring, or intolerance to multidrug regimens.
- Exclusions first: exclude secondary causes (primary aldosteronism, renal artery stenosis, obstructive sleep apnoea, phaeochromocytoma) and confirm adherence before any denervation referral.
- Safety record: no signal of renal dysfunction, renal artery stenosis or electrolyte disturbance in the randomised trials to date.
- Expectation setting: a few mmHg of population-level blood pressure lowering — meaningful for cardiovascular epidemiology, not a cure for individual patients.
Numbers worth knowing, and why the story flipped
Understanding renal denervation means understanding why SYMPLICITY HTN-3 failed. Its patients had resistant hypertension on multiple drugs, and during the trial those drugs were changed, titrated and interrupted; the sham group improved as much as expected from regression to the mean and medication intensification, swamping any device effect. Early single-electrode catheters also delivered patchy, often incomplete circumferential ablation.
The second-generation designs fixed both problems: multi-electrode spiral catheters, protocols that withheld or standardised medication, and sham controls with smaller, cleaner comparison groups. The result is a consistent, modest effect — around 4-6 mmHg ambulatory systolic — replicated across radiofrequency and ultrasound platforms. For a candidate, the synthesis is the answer: denervation lowers blood pressure by a few millimetres reliably, on or off drugs, without the burden of daily tablets; whether that modest effect justifies an interventional procedure is a Heart Team and health-system decision, and in India — where the device is available at only a few centres and paid out of pocket — that bar is high.
How the exam frames it
Two contrasting question stems appear. The first is historical: "SYMPLICITY HTN-3 was negative — is renal denervation dead?" The defensible answer walks through the trial's flaws and the second-generation evidence, ending with "adjunct with modest, real benefit". The second is mechanistic: map efferent versus afferent fibres, and expect a follow-up on why denervation does not cause the sodium-wasting or reflex tachycardia a naive candidate might predict. A discriminating extra mark comes from knowing what denervation is not — not renal artery stenting (that is for stenosis with haemodynamic significance, and ASTRAL/CORAL taught that lesson), and not a licence to stop drugs. The unglamorous essentials — ambulatory confirmation, secondary-cause screening, adherence — remain the highest-yield part of any resistant-hypertension answer.
Frequently asked questions
What is the mechanism of renal denervation?
Radiofrequency or ultrasound energy ablates sympathetic efferent and afferent fibres in the renal artery adventitia, reducing renin release, sodium retention and central sympathetic drive.
Why did SYMPLICITY HTN-3 fail?
Unblinded medication changes, regression to the mean in a resistant-hypertension population, and incomplete ablation with early single-electrode catheters diluted the device effect versus sham.
How much blood pressure fall should be expected?
Roughly 4-6 mmHg ambulatory systolic beyond sham, demonstrated off medication in SPYRAL HTN-OFF MED and RADIANCE-HTN SOLO and maintained on therapy in SPYRAL HTN-ON MED.
Who is a reasonable candidate?
Patients with confirmed treatment-resistant hypertension or drug intolerance, after secondary causes and non-adherence have been rigorously excluded.
Does denervation replace antihypertensive drugs?
No — it is an adjunct with modest effect; guideline-directed pharmacotherapy continues, and drug burden reduction is at best a secondary consideration.